Jyong Biotech Ltd. Ordinary Shares

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Jyong Biotech Responds to Share Price and Volume Movement